Frontiers in Medicine (Oct 2020)

Frequencies of CD33+CD11b+HLA-DR–CD14–CD66b+ and CD33+CD11b+HLA-DR–CD14+CD66b– Cells in Peripheral Blood as Severity Immune Biomarkers in COVID-19

  • Ricardo Wesley Alberca,
  • Milena Mary de Souza Andrade,
  • Anna Cláudia Calvielli Castelo Branco,
  • Anna Cláudia Calvielli Castelo Branco,
  • Anna Julia Pietrobon,
  • Anna Julia Pietrobon,
  • Nátalli Zanete Pereira,
  • Iara Grigoletto Fernandes,
  • Luana de Mendonça Oliveira,
  • Luana de Mendonça Oliveira,
  • Franciane Mouradian Emidio Teixeira,
  • Franciane Mouradian Emidio Teixeira,
  • Danielle Rosa Beserra,
  • Emily Araujo de Oliveira,
  • Sarah Cristina Gozzi-Silva,
  • Yasmim Álefe Leuzzi Ramos,
  • Cyro Alves de Brito,
  • Marcelo Arnone,
  • Raquel Leao Orfali,
  • Valeria Aoki,
  • Alberto Jose da Silva Duarte,
  • Maria Notomi Sato

DOI
https://doi.org/10.3389/fmed.2020.580677
Journal volume & issue
Vol. 7

Abstract

Read online

Common clinical features of patients with Coronavirus disease-2019 (COVID-19) vary from fever, to acute severe respiratory distress syndrome. Several laboratory parameters are reported as indicators of COVID-19 severity. We hereby describe the possible novel severity biomarkers for COVID-19, CD11b+CD33+HLA-DR-CD14+ cells and CD11b+CD33+HLA-DR-CD66b+ cells.

Keywords